Integrated Endoscopy said today it tapped Brad Sharp as its new prez & CEO, as well as joining the company’s board.
The company said it is making the move with Sharp in preparation of the launch of its Nevis single-use arthroscope, which is slated for early 2017.
The company said it also named Rob Cripe as global marketing exec VP, Laxmi Khanolkar as Asia/Middle East sales VP, Mike Amell as manufacturing VP and Tom Colonna as regulatory affairs and quality assurance VP.
“We are fortunate to have Brad Sharp join and lead the Integrated Endoscopy team. Brad has laid out a new vision for the company, which includes a next-generation arthroscope portfolio, along with other equipment utilizing technology that will lead to a paradigm shift in the way ORs operate,” board member & lead investor David Chou said in a press release.
“We are pleased to have pulled together such a strong team in advance of the launch of Nuvis. The market potential for a single-use arthroscope exceeds $1.7 billion in the U.S. alone. The key to commercial success is to provide an out-of-the-box single-use endoscope with high-definition reusable scope image quality at a price point below $300. Couple that with our proprietary distal LED light source, and we believe we can significantly impact the market,” Sharp said in prepared remarks.
RoundTable Healthcare Partners ophthalmic surgical device subsidiary Beaver-Visitec said earlier this month it tapped Dana Mead Jr. as its new prez & CEO. Mead previously operated as a strategic advisor and partner at Kleiner Perkins Caufield & Byers.
Mead will replace Tom Kapfer, who operated as prez & CEO since August 2010.
“Tom’s strategy and vision has helped transform BVI into a true industry leader. The board is grateful for his leadership and wishes him the very best in the future,” BVI chair Ron Labrum said in a press release.
Stentys SA (EPA:STNT) said this summer it tapped Christine Lottin as its new CEO. Lottin previously operated as prez of Hexacath France. The announcement was made along with the company’s FY2016 1st half earnings were reported.
“The first half of the year was marked by an improvement in our results thanks to growth in revenue and a reduction in operating costs. We intend to continue along this line and work to reduce our operating losses during the year. With that in mind, we decided to immediately implement initial measures to reorganize some departments within Stentys,” Lottin said in a prepared statement.
“Steve brings a 20-year record of financial leadership, multi-national business experience and strategic expertise to Cynosure. His success at EMC in areas such as acquisition integration and strategic planning helped drive bottom line results for multiple business units, including Virtustream. Steve’s skills, knowledge and background make him an ideal person to advance the strong foundation of financial and operational excellence built under Tim’s stewardship as CFO for the past 12 years,” prez & CEO Michael Davin said in a press release.
Cynosure said earlier this month it promoted former worldwide sales VP Douglas Delaney to the position of chief commercial officer.
“Doug’s leadership and experience in creating a world-class global sales organization at Cynosure, combined with the results he has achieved over his 13-year tenure, make him uniquely qualified to move into this new position. The performance of our direct sales force in North America, Asia and Europe is directly attributable to Doug’s skill in business development, planning and execution, as well as his ability to build strong relationships with our customers and partners. As CCO, Doug’s focus will expand to ensuring that all activities within the company are aligned to meet our strategic commercial objectives. He has done an outstanding job in leading our sales team, and he will play a central role as we continue to deliver the highest quality products and services to our customers,” prez & CEO Michael Davin said in a prepared statement.
Heart failure device developer Guided Delivery Systems said late last month it tapped Jeffrey Closs as its prez & CEO, and rebranded under the moniker Ancora Heart.
“Jeff is a tremendous asset to the company and has had a year of significant accomplishments with the team. Since assuming the role of Chairman in December 2013, I have been pleased with the progress we are making to advance AccuCinch as an innovative new concept and solution for heart failure and FMR treatment options,” board chair Bob Croce said in a prepared statement.